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Abstract
Objective: To investigate dopaminergic function in a large cohort of patients with corticobasal syndrome (CBS) and
describe its relationship with clinical features in comparison to Parkinson’s disease and healthy control subjects. In addition,
we assessed prevalence and features of individuals with CBS and in vivo evidence of preserved nigral neuronal density.
Background: Substantia nigra pars compacta (SNc) neuronal degeneration is a mandatory pathological criterion for definite
corticobasal degeneration, though sporadic autopsy-proven cases with ante-mortem imaging evidence of preserved nigral
terminals have been recently described.
Methods: In this multicenter study, we investigated presynaptic nigrostriatal function in 36 outpatients fulfilling clinical
criteria for ‘‘probable corticobasal degeneration’’ (age 7167.3 years; disease duration 3.961.6 years), 37 PD and 24 healthy
control subjects using FP-CIT single photon emission computed tomography. Clinical, neuropsychological, and magnetic
resonance imaging assessment was performed to characterize CBS patients. Linear discriminant analysis was used to
categorize normal vs. pathological scans.
Results: FP-CIT binding reduction in patients with CBS was characterized by larger variability, more uniform reduction
throughout the striatum and greater hemispheric asymmetry compared to PD. Moreover, there was no significant
correlation between tracer uptake values and clinical features such as disease duration and severity. Despite all CBS subjects
showed obvious bilateral extrapyramidal signs, FP-CIT uptake was found to be normal bilaterally in four CBS patients and
only unilaterally in other four cases. Extensive clinical, neuropsychological and imaging assessment did not reveal
remarkable differences between CBS subjects with normal vs. pathological FP-CIT uptake.
Conclusions: Our findings support the hypothesis that extrapyramidal motor symptoms in CBS are not invariably associated
with SNc neuronal degeneration and that supranigral factors may play a major role in several cases. CBS individuals with
normal FP-CIT uptake do not show any clinical or cognitive feature suggesting a different pathology than CBD.
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Introduction
Corticobasal degeneration (CBD) is a progressive neurodegener-
ative disorder characterized by levodopa-resistant asymmetric
akinetic-rigid parkinsonism and limb dystonia, variably associated
with cortical features [1]. Clinicopathological studies reported a high
rate of misdiagnosis in patients with clinical diagnosis of CBD [2–9],
so that it has been suggested that patients fulfilling clinical features of
CBD should receive the clinical diagnosis of ‘corticobasal syndrome’
(CBS), until post-mortem examination unravels the underlying
causative pathology [3,10–12]. An increasing amount of studies
investigated clinical, neuropsychological and imaging features of
patients with CBD-like phenotype searching for distinctive in vivo
features, with variable and overall not conclusive results [9,13–15].
Striatal dopamine transporter (DAT) imaging is a sensitive
biomarker of substantia nigra pars compacta (SNc) neuronal
density that may improve the accuracy of in vivo diagnosis in
patients with CBS, given that SNc cell loss is a pathological finding
considered to be mandatory for the definite diagnosis of CBD
[3,16,17]. Nevertheless, ante-mortem evidences of preserved presyn-
aptic nigrostriatal terminals in CBS patients who subsequently
developed severe SNc degeneration [18,19] raise the need to
clarify possible delayed ‘timing’ of SNc terminal loss in relation to
the emergence of motor symptoms.
In the present study, we investigated in vivo DAT density using
single photon emission computed tomography (SPECT) in a large
cohort of patients with CBS, along with extensive clinical,
neuropsychological and brain magnetic resonance imaging
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pattern of DAT reduction in CBS compared to PD and healthy
control subjects and to correlate DAT binding with clinical
features. In addition, we aimed to assess the prevalence of
preserved SNc neuronal density in CBS population and highlight
possible differential features between CBS subjects with normal vs.
pathological SPECT scans.
Methods
Subjects
Thirty-six outpatients with clinical diagnosis of ‘probable CBD’
according to current diagnostic criteria [1] were consecutively
recruited from three Italian Movement Disorders Clinics (Parkin-
son Institute of Milan, Department of Neurosciences of Pisa, and
Neurological Unit of Versilia Hospital) between 2005 and 2008.
We excluded those patients with exposure to typical neuroleptics;
those with brain MRI evidence of moderate-to-severe vascular
abnormalities, space-occupying lesions or normal pressure hydro-
cephalus. We did not exclude patients presenting early cognitive
impairment [1], as dementia might be a presenting feature of CBD
[20]. We recorded the most prominent motor and non-motor
symptoms and signs of CBD at neurological examination [1,5] as
well as presenting clinical features according to patients’ previous
data (clinical signs were considered positive only if they were
identified by a neurologist) or, when not available, as reported by
the subject or caregiver as significant complaints. We considered
as ‘early’ those features that occurred within the first 12 months
from the clinical onset.
Motor function assessment in CBS and PD patients included the
Hoehn and Yahr stage (H&Y) and the Unified Parkinson Disease
Rating Scale motor score (UPDRS III) assessed in the morning
while on their current therapy. Twenty-six CBS patients were
receiving levodopa, 12 were taking anticholinergics and/or
benzodiazepines while none was taking dopamine agonists,
COMT or MAO-B inhibitors, amantadine, selective serotonin
uptake inhibitors, or cholinesterase inhibitors. In the PD control
group, individual levodopa equivalent daily dose (LEDD) at the
time of SPECT scan was calculated as the sum of the levodopa
and dopamine agonists daily dosage, as reported elsewhere [21].
Dopaminergic medication has been demonstrated not to play a
significant influence on FP-CIT uptake [22,23].
At the time of FP-CIT SPECT imaging, all CBS patients
underwent full neuropsychological evaluation using the following
scales: the mini mental state examination (MMSE) [24], the Corsi
block tapping test, digit span, story recall, frontal assessment
battery (FAB) [25], attentional matrices, verbal fluencies using
category and phonemic cues (1-minute), and neuropsychiatric
inventory (NPI) [26]. We applied adjustment for age and
education when appropriate and used pathological cut-off values
as established elsewhere [27–33]. We additionally recorded the
occurrence of dementia according to Diagnostic and Statistical
Manual of Mental Disorders Fourth Edition (DSM IV) criteria
[34]. As CBS patients were assessed on-medications, we could not
exclude a potential confounding effect of anticholinergic medica-
tions on cognitive function. We used two control populations to
compare FP-CIT SPECT imaging binding values: one consisting
of 37 patients with idiopathic PD according to the UK Brain Bank
diagnostic criteria [35] of similar age and disease duration and a
second group of 32 age-matched healthy control (HC) subjects
who had no history or evidence of neurologic or psychiatric
disease. All CBS patients underwent 1.5 Tesla brain MRI,
performed according to a previously published protocol [36].
MR images were evaluated by an independent neuroradiologist
(unaware of the clinical and FP-CIT imaging status of patients)
who was asked to record the following features: asymmetric or
symmetric frontal and/or parietal cortical atrophy, diffuse cortical
atrophy, subcortical atrophy, midbrain atrophy, normal scan.
The study was approved by the Ethics Committees of the
institutions involved in the study. Subjects’ consent was obtained
according to the Declaration of Helsinki.
FP-CIT SPECT
SPECT studies were carried out either at the Nuclear Medicine,
University of Pisa, or at the IRCCS-Ospedale Maggiore, Milan.
Intravenous administration of 110–185 MBq of
123I-2b-carbome-
toxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (
123I-FP-
CIT) (DaTscanH, GE Healthcare) was performed 30–40 min
after thyroid blockade in all subjects after overnight withdrawal of
dopaminergic medications. Brain SPECT was performed 3–
4 hours later by means of a dedicated triple detector gamma
camera (Prism 3000, Philips, Eindhoven, The Netherlands)
equipped with ultra-high-resolution fan beam collimators (four
subsets of acquisitions) or a dual-head gamma camera (Optima
NT, GE Healthcare, Milwaukee, WI, USA) equipped with high
resolution low energy parallel holes collimators, matrix size
1286128, radius of rotation 13–15 cm, 120–128 projections over
a 360u circular orbit. The overall scanning time for each patient
was 30 to 45 minutes. Brain sections were obtained by applying an
iterative algorithm (OS-EM, 2–4 iterations and 8–15 subsets) on
projection data and a 3D postfilter (Butterworth, order 5, cut-off
0.3 Ny) and attenuation correction (Chang method,
m=0.12 cm
21). Transaxial data were reoriented along the
fronto-occipital line. Usually five to eight slices were summed in
order to include the basal ganglia. Regular circular regions of
interest were drawn on the bilateral total striatum, on the caudate
nucleus and the putamen and used to calculate the average
striatal-to-nonspecific uptake areas with negligible amount of
dopamine receptors, such as occipital lobes. The formula used was
as follows: FP-CIT binding=[(mean radioactivity in the stria-
tum)2(mean radioactivity in the occipital cortex)]/(mean radio-
activity in the occipital cortex). Asymmetry indices (AIs) of FP-CIT
binding were calculated as reported by Sherfler and colleagues
[37]. The ‘contralateral’ side in CBS and PD patients was defined
as the side opposite to the clinically most affected side. For
statistical purposes, in healthy subjects we conventionally referred
to the side with lower FP-CIT uptake as the ‘contralateral’. The
relationship between FP-CIT binding in the caudate nucleus and
the putamen contralateral to the most affected body side was
calculated for each individual as follows: Caudate-to-putamen
ratio=Caudate binding/Putamen binding. Patients and control
subjects were balanced between Milan and Pisa nuclear medicine
departments.
Data analysis
All statistical analyses were carried out using BMDP software
package for Windows Release 2009 (BMDP Statistical Software,
University of California Press, Release 2009 – Berkeley, Los
Angeles, Oxford). FP-CIT SPECT binding data (uptake values,
AIs in striatum, caudate nucleus and putamen, and caudate-to-
putamen ratio) obtained from CBS patients were compared with
those obtained from HC subjects and PD patients. Parametric
methods were used for variables after testing for normal
distribution (Shapiro-Wilk W statistic [38]). Continuous variables
were compared using the Student’s t-tests or analysis of variance
(ANOVA). For multiple comparisons between groups, a Bonfer-
roni correction was applied. The Kruskal-Wallis test and the
Mann-Whitney U test were used to compare variables without
FP-CIT SPECT in Corticobasal Syndrome
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test, with Yates correction for 262 tables. In addition, differences
in neuropsychological testing scores between the CBS patients
with normal vs. pathological FP-CIT uptake were calculated using
dichotomous ‘normal’ vs. ‘pathologic’ variables, according to
normative cut-off values. To discriminate between CBS and HC
groups we performed linear discriminant analysis with a forward
selection mechanism based on Wilk’s lambda as selection criteria
for potential predictors, i.e. [123I] FP-CIT mean binding values in
the bilateral caudate nucleus and the putamen, the caudate-to-
putamen ratio, and the hemispheric asymmetry index of the
striatal uptake [37]. An additional discriminant analysis was
performed using caudate nuclei and putamina uptake values as
potential predictors and excluding indirect variables such as
asymmetry indices and caudate-to-putamen ratio. For group
membership, the same a priori probability was assumed for all
cases. For validation of the model we used a leave-one-out
procedure. The cut-off value between two groups was determined
as follows: (1) the mean and its confidence interval (CI 95%) of
both groups were calculated; and (2) the cut-off value was
determined by averaging over the lower bound of the CI of one
group and the upper bound of the other group. In CBS and PD
groups the relationship between clinical variables (disease
duration, the UPDRS motor score, the H&Y stage, neuropsycho-
logical testing scores) and FP-CIT binding values in the whole
striatum, caudate nucleus and putamen were explored using the
Pearson correlation coefficient. Neuropsychological testing scores
were correlated with right vs. left striatal structures rather than
ispilateral vs. contralateral to the most affected body side.
Results
Cohort characteristics in CBS, PD and HC subject groups have
been summarized in Table 1. Compared to PD control subjects,
CBS patients had lower LEDD (p=0.0001) and worse disease
severity (p,0.0001).
1. FP-CIT SPECT findings (Table 2, Figures 1 and 2)
CBS patients vs. PD control subjects. When compared to
PD control subjects, CBS patients showed larger variability in the
severity and pattern of FP-CIT binding reduction, with more
uniform reduction throughout the striatum and greater
hemispheric asymmetry. FP-CIT uptake in CBS was similar in
the striatum contralateral to the most affected body side and
higher ipsilaterally than PD (p,0.001); it was lower in the
contralateral caudate nucleus (p=0.005) and similar ipsilaterally,
higher in contralateral and ipsilateral putamen (p,0.001).
Caudate AI was significantly higher in CBS than PD
(p,0.0001), while putaminal AI was similar. CBS had lower
caudate-to-putamen ratio than PD (p,0.0001).
CBS patients vs. HC subjects. CBS had reduced FP-CIT
uptake and higher AIs in the caudate nucleus and putamen and
similar caudate-to-putamen ratio in comparison to HC
(p,0.0001 in each comparison). Using linear discriminant
analysis, we found that thirty-two patients with CBS had
pathological FP-CIT binding (hereafter referred to as ‘CBSP’)
while four cases had normal FP-CIT binding (hereafter referred
to as ‘CBSN’; Wilk’s Lambda=0.075, F-Statistic=42.840). In the
CBSP group were also included three cases (age 6265.5 years;
disease duration 3.361.1 years; H&Y stage 2.560.5) whose FP-
CIT binding was in the normal range but whose hemispheric AI
was significantly higher than PD control subjects (Wilk’s
Lambda=0.1653; cases 5, 6 and 7 in Table 3). Other four
CBSP subjects had normal striatal uptake ipsilateral to the most
affected body side but not contralaterally, despite bilateral
extrapyramidal signs.
CBS subgroups analysis: CBSN vs. CBSP. FP-CIT binding
values were significantly higher in the bilateral caudate nucleus
and putamen of CBSN compared to CBSP (p,0.001 in each
comparison) and similar to HC subjects. Kruskall-Wallis test found
significant differences on the mean ranks of caudate nucleus and
putaminal FP-CIT uptake among CBSN, CBSP, PD, HC
(p,0.0001). Post-hoc analysis showed that FP-CIT uptake in the
caudate nucleus of CBSN was similar to HC and PD, while
putaminal uptake was higher than PD (p=0.006) and similar to
HC, bilaterally. Striatal uptake in CBSP was similar to PD and
lower than HC (p,0.0001). CBSP patients had higher caudate
and putamen AIs compared to CBSN and HC (p,0.0001 in each
comparison), while they showed only higher caudate AI
(p,0.0001) compared to PD. CBSN had similar caudate and
putaminal AIs compared to HC, while they had similar caudate
and lower putaminal AI (p=0.0001) compared to PD. The mean
caudate-to-putamen ratio was similar in CBSN vs. CSBP vs. HC,
while this was higher in PD than all the other groups (p,0.001 in
each comparison).
2. Clinical, neuropsychological and brain MRI features
In the whole group of CBS patients (n=36), extrapyramidal
signs were similarly recorded in 94% of cases in the early stages of
the disease, irrespective of FP-CIT uptake. Patients presented with
either akinetic (92%), dystonic (11%), apraxic (67%) arm, or gait
disorder/postural instability (30%) (Table S1). During the disease
course, all patients developed full-blown typical clinical picture of
CBS and none experienced significant and sustained clinical
improvement from chronic levodopa treatment. Disease duration
was negatively correlated with FP-CIT uptake in the striatum, the
caudate nucleus and the putamen only in PD (p,0.01 in all the
analyses) but not in CBS (Figure 3A). This difference remained
significant also after excluding CBSN subjects from the analysis
(data not shown). H&Y stage negatively correlated with striatal FP-
CIT binding in the PD group (p,0.01) while showed a trend for
negative correlation with striatal binding in CBS patients
(Figure 3B). The UPDRS motor score showed negative
correlation with striatal uptake in PD (p,0.01) and CBS
(p=0.047) groups. Neuropsychological profile of the whole CBS
cohort was overall characterized by mildly reduced global
cognitive performance, characterized by reduced frontal lobe
Table 1. Demographic features and ratings in CBS, PD, and
healthy control subjects.
Features CBS (n=36) HC (n=32) PD (n=37)
M:F 16:20 15:17 18:19
Age at onset 67.2 (6.9) - 65.5 (5.5)
Age at FP-CIT SPECT, y 71.1 (7.3) 69.8 (5.7) 69.9 (5.3)
Side of symptoms
onset, L:R
19:17 - 16:21
Disease duration, years 3.89 (1.6) - 4.4 (2.9)
LEDD, mg 328.5 (263.4)* - 538.8 (250.0)
Hoehn and Yahr stage 3.1 (0.8)* - 1.91 (0.7)
UPDRS part III 38.8 (12.6)* - 21.7 (7.8)
Intergroup differences of demographic features were calculated by one-way
ANOVA with post hoc significance correction (*p,0.05 in CBS vs. PD). Values are
mean (SD).
doi:10.1371/journal.pone.0018301.t001
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and long-term memory tasks (Table S2). We did not find any
correlation between FP-CIT binding and any of the neuropsy-
chological scores.
We applied non-parametric tests to investigate the differences
between CBSN and CBSP (Table S1). Demographic and general
clinical features were similar between the two CBS subgroups,
with the exception of mean longer disease duration in CBSN at the
time of SPECT (p=0.038). Clinical presentation did not
significantly differ between the two CBS subgroups, with the only
exception of early memory impairment, that was more frequently
reported in the clinical history of CBSN patients (p,0.005). At the
time of SPECT scan, CBSP patients had higher prevalence of
postural instability and falls than CBSN (p=0.005) while parietal
lobe signs other than apraxia were more frequently reported in
CBSN vs. CBSP (p,0.001). Neuropsychological testing scores did
not differ between CBSN and CBSP (Table S2). Brain MRI
findings were not different between CBSN vs. CBSP (Table S3).
Finally, statistical analyses performed lumping together all CBS
patients showing normal FP-CIT uptake values (n=7 subjects,
Table 3) confirmed the lack of any significant difference between
CBSN vs. CBSP in all the clinical, neuropsychological and MRI
variables investigated, including disease duration (4.962.3 vs.
3.761.4, p=0.08).
Figure 1. Scatter plot showing individual FP-CIT uptake values in the striatum contralateral and ipsilateral to the most affected
body side in CBS, PD, and HC subjects. The uptake values of HC subjects have been averaged between the two sides. The line represents the
mean.
doi:10.1371/journal.pone.0018301.g001
Table 2. Semiquantitative FP-CIT binding values in caudate nucleus and putamen, hemispheric asymmetry indices and caudate-
to-putamen ratio in CBS, PD, and healthy control subjects.
FP-CIT SPECT binding values CBS tot (n=36) CBSN (n=4) CBSP (n=32) HC (n=32) PD (n=37)
Contralateral caudate 1.04 (0.4) 1.66 (0.1) 0.96 (0.3) 1.77 (0.2) 1.25 (0.3)
Ipsilateral caudate 1.26 (0.4) 1.67 (0.2) 1.21 (0.4) 1.82 (0.2) 1.33 (0.3)
Contralateral putamen 0.92 (0.4) 1.63 (0.2) 0.84 (0.4) 1.68 (0.1) 0.68 (0.2)
Ipsilateral putamen 1.17 (0.4) 1.64 (0.1) 1.11 (0.4) 1.71 (0.2) 0.87 (0.2)
Asymmetry index Caudate, % 17.93 (10.8) 4.45 (3.3) 20.17 (9.1) 5.28 (3.3) 5.98 (2.5)
Asymmetry index Putamen, % 22.50 (15.1) 2.27 (1.3) 25.25 (13.6) 3.8 (2.3) 21.14 (8.3)
Caudate-to-putamen ratio 1.19 (0.3) 1.02 (0.1) 1.21 (0.3) 1.07 (0.1) 1.88 (0.5)
The whole cohort of CBS patients has been divided into those with normal (CBSN) and pathological (CBSP) FP-CIT binding. Values are mean (SD).
doi:10.1371/journal.pone.0018301.t002
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This is the first study investigating presynaptic dopaminergic
function along with extensive clinical and neuropsychological
characterization in a large cohort of patients fulfilling clinical
criteria for ‘probable CBD’. The primary outcome of this study
was to describe the pattern of striatal FP-CIT uptake reduction in
CBS and correlate FP-CIT binding with clinical features.
Compared to PD control subjects, individuals with CBS showed
a large FP-CIT binding variability in terms of overall striatal
binding as well as hemispheric asymmetry and caudate-to-
putamen ratio (Figures 1 and 2). In consistence with typical
CBD pathological features [17], we found higher hemispheric
asymmetry in caudate nucleus and putaminal FP-CIT uptake
together with a more uniform reduction within striatal regions in
CBS, thus reflecting the highly asymmetrical involvement and
SNc neuronal loss involving both dorsal and ventral tiers in CBD
[16,17] in contrast to PD, where cell loss is typically confined to
SNc ventral tiers [39]. These features well explain the difference
in the caudate-to-putamen ratio of FP-CIT uptake between the
two disorders. When correlation analysis was performed between
nigrostriatal function and clinical features in CBS, FP-CIT
binding showed did not show any correlation with disease
duration and just a trend with disease severity, while this
association was highly significant in PD control subjects
(Figure 3A and B). Previous imaging studies already highlighted
a less pronounced SNc neuronal loss in patients with CBS
compared not only to severe atypical parkinsonian syndromes
(such as progressive supranuclear palsy and multiple system
atrophy) but also to idiopathic PD [40–44]. Interestingly, some
CBS patients had symmetrical FP-CIT reduction despite strongly
asymmetrical symptoms, a finding already described in a previous
fluorodopa-PET study [41]. A recent description of autopsy-
proven CBD with ante-mortem evidence of preserved presynaptic
nigrostriatal terminals suggested a possible delayed timing of SNc
cell degeneration, unrelated to the onset of motor symptoms
[18,19]. The lack of relationship between FP-CIT binding and
disease duration and the very weak correlation with disease
severity we found in our CBS cohort is in line with this
hypothesis. Moreover, the presence of obvious bilateral symptoms
but evidence of reduced DAT density only unilaterally in some
CBS cases would further suggest that SNc pathology may require
a variable time to occur bilaterally. These findings highlight a
mismatch between SNc neuronal loss and clinical features (such
as asymmetry of motor symptoms, disease duration and severity)
and support the hypothesis of a prominent role played by cortical
and/or striatal pathology in the clinical picture of this syndrome.
The lack of any correlation between FP-CIT binding and
cognitive performance is an expected finding that is consistent
with ‘cortical’ rather than ‘subcortical’ pathology underlying
cognitive deficits in CBS compared to PD.
As secondary objective, we aimed to assess the prevalence and
characterize those CBS subjects with normal FP-CIT scans aiming
to find any distinctive clinical or neuropsychological feature. To
achieve this objective, we used very restrictive a priori criteria to
minimize false positive cases and found preserved SNc neuronal
density in approximately 10% of our cases. So far, normal
dopamine transporter density has been reported only sporadically
Figure 2. Scatter plots showing hemispheric asymmetry indices in the total striatum, caudate nucleus and putamen in CBSN, CBSP,
PD, and HC subjects.
doi:10.1371/journal.pone.0018301.g002
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the 4 CBS patients with normal FP-CIT measures.
Case 1 Case 2 Case 3 Case 4 (Case 5) (Case 6) (Case 7)
Clinical features
Gender F M F M F M F
Age at onset 77 64 74 58 67 62 56
Age at SPECT 81 72 78 66 71 64 60
Disease duration
at FP-CIT SPECT
48 4 8 4 2 4
Levodopa daily dosage 750 0 0 0 400 300 300
Hoehn and Yahr stage 3 4 2,5 2,5 2,5 2 3
UPDRS III 37 38 25 25 32 22 30
Language dominant
hemisphere
LL L L L L L
Clinical presentation
Gait difficulty.
Cognitive
impairment.
Hand clumsiness
And jerk tremor,
gait difficulty
Depression.
Hand clumsiness,
rigidity and
tremor.
Episodes of
Disorientation/
confusion.
Hand
clumsiness
and rigidity.
Hand
clumsiness,
gait difficulty.
Language
production
and
behavioral
disturbances.
Hand
clumsiness.
Hand
clumsiness,
gait difficulty,
bradykinesia.
Motor signs
Side of motor
symptoms onset
RL L R L L L
Akinesia (+)( +)( +)( +)( +)( +)( +)
Rigidity (+) + (+)( +)( +)( +)( +)
Tremor 2 (+)( +) + 2 + (+)
Limb dystonia/
Clenched fist
+/++ /+ (+)/++ /++ /22 /2 +/2
Myoclonus 2 ++ + 2 + (+)
Gait disturbance (+)( +) 22 (+) 2 (+)
Postural instability 22 2 2 2 2 +
Cortical/cognitive
features
Dementia (+) + (+) 22 ++
Limb apraxia + (+)( +) + (+) ++
Alien limb phenomenon ++ 2 ++ ++
Cortical sensory deficit ++ + + 22 2
Non-fluent aphasia ++ + + 2 (+)( +)
Early memory impairment 22 + 22 2+
Early visuo-spatial
dysfunction
++ + 22 ++
Behavioral abnormalities/
personality changes
22 2 2 2 (+) +
Other features
Dysarthria and/or
Dysphagia
2 + 2 ++ 22
Oculomotor
impairment
2 + 22 ++ 2
Depression (+)( +) 2 + (+) + (+)
Frontal-lobe release signs ++ + 2 ++ +
Other frontal/
parietal lobe signs Gait apraxia
Left-sided neglect,
gait apraxia
Left-sided
neglect,
prosopoagnosis.
Right-sided
Neglect - - Gait apraxia
Neuropsychological testing
MMSE 16 20 13 28.9 23.7 17.9 18
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in consecutive cohorts ever documented any normal scan [40–44].
To our knowledge, there are only few reports of patients with
clinical diagnosis of CBD with preserved SNc neuronal density at
post-mortem, and most of them displayed either Alzheimer’s or Pick’s
disease pathology [2,3,5,7,9,10,14,15,46–48]. The first possible
explanation would come from a possible pathological involvement
of the downstream postsynaptic neurons, even though the
pathological involvement of postsynaptic striatal neurons in CBD
is variable and unpredictable [17,49]. A second hypothesis would
posit that extrapyramidal symptoms in CBS with normal SNc
density might be associated with frontal and/or parietal cortical
rather than striatal pathology [4,7,19,50,51]. In the attempt to rule
thisout, we extensivelyinvestigatedclinical, neuropsychological and
MR imaging features of our CBS cohort and did not find any major
clue suggesting an alternative diagnosis than CBD. Although early
memory impairment was more frequently recorded in the history of
CBSN cases (Table S1), full neuropsychological assessment
revealed similar features in both subgroups, including preserved
memory functions, consistent with the pattern shown in definite
CBD (Table S2) [52]. Notably, our cohort is representative of
specialized movement disorders centres so that the number of cases
presenting with prominent cognitive impairment and mild-to-
absent extrapyramidal symptoms is relatively low, as these subjects
would rather refer to third-level dementia clinics [20,52]. SNc
depigmentation is less evident in CBD cases presenting with severe
cognitive symptoms [53] and it is thus conceivable that we
underestimated the real prevalence of normal FP-CIT scans in
CBS population [6,20]. Moreover, CBS subjects with normal scans
showed a mean longer disease duration than CBS patients with
presynaptic nigrostriatal degeneration despite similar degrees of
motor disability, suggesting a more indolent course.
We acknowledge that the interpretation of our findings is
limited by the lack of pathological confirmation of the diagnosis.
Indeed, some CBS patients with normal FP-CIT binding might
still turn out to be focal cortical variants of other dementia than
CBD [3,7,10,46,47,54–59], because clinical features and the
distribution of pathological lesions are closely associated whatever
the histologic nature [3,4,9,14]. Post-mortem assessment in CBS
cases with preserved SNc neuronal density could also unravel the
pathological underpinnings of extrapyramidal symptoms. A
second limitation in the interpretation of the comparison between
CBSN and CBSP comes from the marked unbalance in the
number of cases between the two groups.
Taken as a whole, our findings support the hypothesis of a
mismatch between SNc neuronal loss and clinical features with a
variable contribution played by supranigral pathology in
extrapyramidal phenotype. We speculate that the well-known
heterogeneity of CBD pathology [60] might additionally include
variants with predominant involvement of the cerebral cortex and
disease progression in the rostro-caudal direction to the
brainstem, in a kind of ‘cortico-to-basal’ progression of neuronal
degeneration. This hypothesis is supported by pathological
studies showing a less evident SNc depigmentation in CBD cases
presenting with cognitive rather than motor symptoms [53] and
already demonstrated in Lewy bodies dementia [61,62]. Clinico-
pathological studies including in vivo DAT imaging are needed to
assess the predictive value of normal presynaptic nigrostriatal
function in the diagnostic work up of patients with CBD-like
phenotype.
Other frontal/
parietal lobe signs Gait apraxia
Left-sided neglect,
gait apraxia
Left-sided
neglect,
prosopoagnosis.
Right-sided
Neglect - - Gait apraxia
Corsi Block Tapping Test 2.5 2 2 4 4.75 2.25 2.11
Digit Span 4 4.4 5 4.75 3.75 3.5 3.5
Story recall 7.5 5 4.3 8.2 13.8 8.8 n.a.
Attentional Matrices 13.5 15 26 33 31.5 11.5 n.a.
Category Verbal Fluency n.a. 17 14 24 n.a. n.a. n.a.
Phonemic Verbal Fluency 8 13 18 14 13 10.9 7.2
Frontal Assessment Battery 6 7 9 12.9 11.8 10 5
Neuropsychiatric Inventory 20 15 12 14 6 16 18
FP-CIT SPECT binding
Contralateral striatum 1,78 1,53 1,49 1,48 1,72 1,66 1,92
Ipsilateral striatum 1,65 1,71 1,56 1,48 2,07 1,72 2,04
Contralateral caudate 1,60 1,77 1,72 1,54 1,73 1,50 2,08
Ipsilateral caudate 1,47 1,87 1,75 1,57 2,36 1,78 2,48
Contralaterale putamen 1,87 1,51 1,57 1,58 1,65 1,74 1,84
Ipsilaterale putamen 1,82 1,57 1,60 1,57 1,90 1,68 2,06
Asymmetry index (Striatum) 7,30 10,53 4,49 0,00 16,91 3,49 5,88
Asymmetry index (Caudate
nucleus)
28,84 5,35 1,71 1,91 26,69 15,73 16,13
Asymmetry index (Putamen) 22,75 3,82 1,88 20,64 13,16 23,57 10,68
Caudate:Putamen ratio 0,86 1,17 1,10 0,97 1,05 0,86 1,13
We additionally reported 3 CBS cases with normal FP-CIT uptake in the caudate nucleus and the putamen bilaterally, but included in the CBSP subgroup because of
abnormal asymmetry indices and/or caudate-to-putamen ratio (cases 5, 6 and 7). +=sign present; (+)=initial sign; 2=sign absent.
doi:10.1371/journal.pone.0018301.t003
Table 3. Cont.
FP-CIT SPECT in Corticobasal Syndrome
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e18301Figure 3. Correlation of FP-CIT binding in the contralateral striatum. Shown with the disease duration (A), and disease severity, according to
the H&Y stage (B), in CBS patients and in PD controls.
doi:10.1371/journal.pone.0018301.g003
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e18301Conclusions
In vivo assessment of dopamine transporter SPECT imaging in a
large CBS population was found to be normal in about 10% of
cases despite prominent bilateral extrapyramidal signs. In these
cases, clinical and neuropsychological features were not distinct
from those with evidence of SNc neuronal loss. The lack of any
correlation between presynaptic nigrostriatal dysfunction and
disease duration might suggest an unpredictable and possibly
delayed SNc degeneration in CBD and further supports the
hypothesis of a variable contribution of supranigral pathology to its
motor phenotype.
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